Quantcast

Epirubicin and ifosfamide


#1

An Italian trial tried to compare a regimen made of epirubicin (120mg/sqm) and ifosfamide (9gm/sqm) versus an histology-driven regimen (high dose ifosfamide for synovial sarcoma) in patients with high risk soft tissue sarcoma and found that epirubicin+ifsofamide was associated with a better rate of recurrence-free survival and overall survival:
http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Significant-Survival-Gains-from-Neoadjuvant-Chemotherapy-for-High-risk-Soft-Tissue-Sarcoma
Epirubicin is similar to doxorubicin. This suggests that high dose ifosfamide is not as good as the conventional AIM regimen as first line therapy.